{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Zhao W"],"funding":["Special Project of Central Government for Local Science and Technology Development of Hubei Province","National Natural Science Foundation of China"],"pagination":["102315"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10679864"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["66"],"pubmed_abstract":["Background
Immunotherapy has revolutionized the treatment of cancer. However, microsatellite stable (MSS) metastatic colorectal cancer (mCRC) shows a low response to PD-1 inhibitors. Antiangiogenic therapy can enhance anti-PD-1 efficacy, but it still cannot meet clinical needs. Increasing evidence supported a close relationship between gut microbiome and anti-PD-1 efficacy. This study aimed to explore the efficacy and safety of the combination of fecal microbiota transplantation (FMT) and tislelizumab and fruquintinib in refractory MSS mCRC.Methods
In the phase II trial, MSS mCRC patients were administered FMT plus tislelizumab and fruquintinib as a third-line or above treatment. The primary endpoint was progression-free survival (PFS). Secondary endpoints were overall surv"],"journal":["EClinicalMedicine"],"pubmed_title":["Fecal microbiota transplantation plus tislelizumab and fruquintinib in refractory microsatellite stable metastatic colorectal cancer: an open-label, single-arm, phase II trial (RENMIN-215)."],"pmcid":["PMC10679864"],"funding_grant_id":["ZYYD2020000169","82102954"],"pubmed_authors":["Tang Z","Alnaggar M","Qiu H","Lei J","Xiao J","Ren Y","Zhao W","Shi W","Chen Y","Yin L","Ke S","Wang L"],"additional_accession":[]},"is_claimable":false,"name":"Fecal microbiota transplantation plus tislelizumab and fruquintinib in refractory microsatellite stable metastatic colorectal cancer: an open-label, single-arm, phase II trial (RENMIN-215).","description":"Background
Immunotherapy has revolutionized the treatment of cancer. However, microsatellite stable (MSS) metastatic colorectal cancer (mCRC) shows a low response to PD-1 inhibitors. Antiangiogenic therapy can enhance anti-PD-1 efficacy, but it still cannot meet clinical needs. Increasing evidence supported a close relationship between gut microbiome and anti-PD-1 efficacy. This study aimed to explore the efficacy and safety of the combination of fecal microbiota transplantation (FMT) and tislelizumab and fruquintinib in refractory MSS mCRC.Methods
In the phase II trial, MSS mCRC patients were administered FMT plus tislelizumab and fruquintinib as a third-line or above treatment. The primary endpoint was progression-free survival (PFS). Secondary endpoints were overall surv","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Dec","modification":"2025-04-22T18:09:03.91Z","creation":"2025-04-06T02:21:40.832Z"},"accession":"S-EPMC10679864","cross_references":{"pubmed":["38024475"],"doi":["10.1016/j.eclinm.2023.102315"]}}